Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-354-8840
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.73 million
Profitability
Miscellaneous
Employees29
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) announced its earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.04. The biopharmaceutical company earned $0.23 million during the quarter, compared to analysts' expectations of $3 million. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
6 analysts have issued 12-month price objectives for Trevena's stock. Their predictions range from $1.00 to $15.00. On average, they expect Trevena's stock price to reach $6.45 in the next twelve months. This suggests a possible upside of 330.0% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
Has Trevena been receiving favorable news coverage?
News stories about TRVN stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trevena earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Crinetics Pharmaceuticals (CRNX), Basilea Pharmaceutica (BPMUF), Catalyst Pharmaceuticals (CPRX), GlycoMimetics (GLYC), Magenta Therapeutics (MGTA), Zymeworks (ZYME), Urogen Pharma (URGN), Axsome Therapeutics (AXSM), Emisphere Technologies (EMIS), Collegium Pharmaceutical (COLL), Cyclerion Therapeutics (CYCN), ProQR Therapeutics (PRQR), Corium International (CORI), CytomX Therapeutics (CTMX) and BioSpecifics Technologies (BSTC).
What other stocks do shareholders of Trevena own?
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Ms. Carrie L. Bourdow, CEO, Pres & Director (Age 56)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Mr. John P. Hamill, VP of Fin. (Age 55)
- Erin Clark, Sr. Director of Corp. Strategy & Investor Relations
- Mr. Michael Catalano, VP of Marketing
Who are Trevena's major shareholders?
Trevena's stock is owned by many different of retail and institutional investors. Top institutional investors include Tibra Equities Europe Ltd (0.20%) and Virtu Financial LLC (0.02%). Company insiders that own Trevena stock include Leon O Moulder Jr, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.
Which major investors are selling Trevena stock?
Which major investors are buying Trevena stock?
TRVN stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. Company insiders that have bought Trevena stock in the last two years include Leon O Moulder Jr and Maxine Gowen. View Insider Buying and Selling for Trevena.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $1.50.
How big of a company is Trevena?
Trevena has a market capitalization of $138.53 million and generates $5.73 million in revenue each year. The biopharmaceutical company earns $-30,780,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Trevena employs 29 workers across the globe.
What is Trevena's official website?
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
